PRODUCT INFORMATION



XL092

Item No. 37749

CAS Registry No.: 2367004-54-2

Formal Name: N-(4-fluorophenyl)-N'-[4-[[7-

methoxy-6-[(methylamino)

carbonyl]-4-quinolinyl]oxy]phenyl]-

1,1-cyclopropanedicarboxamide

Synonym: Zanzalintinib MF: C₂₉H₂₅FN₄O₅

FW: 528.5 **Purity:** ≥98% Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

XL092 is supplied as a solid. A stock solution may be made by dissolving the XL092 in the solvent of choice, which should be purged with an inert gas. XL092 is soluble in DMSO.

Description

XL092 is a multi-kinase inhibitor. It selectively inhibits the receptor tyrosine kinases (RTKs) MET, VEGFR2, AxI, and Mer (IC_{50} s = 3, 15, 5.8, and 0.6 nM, respectively) over serine/threonine kinases for which it has no activity, but does inhibit 28 other RTKs with IC_{50} values ranging from 3 to 54 nM, as well as additional kinases by greater than 70% at 1 μ M. XL092 inhibits the proliferation of SNU-5 human gastric carcinoma cells (IC₅₀ = 98.9 nM), which highly express MET, and human umbilical vein endothelial cells (HUVECs; IC_{50} = 10.4 nM). It reduces tumor volume and intratumoral MET phosphorylation in NCI H441 human lung cancer and SNU-5 mouse xenograft models when administered at doses of 3 and 10 mg/kg. XL092 (30 mg/kg) increases the number of peripheral B cells and CD4+ T cells, and decreases the number of peripheral myeloid cells, in an MC-38 syngeneic mouse model of colon carcinoma, indicating a conversion to an immune-permissive tumor microenvironment.

Reference

1. Hsu, J., Chong, C., Serrill, J., et al. Preclinical characterization of XL092, a novel receptor tyrosine kinase inhibitor of MET, VEGFR2, AXL, and MER. Mol. Cancer Ther. 22(2), 179-191 (2023).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/12/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM